Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00140075 · ClinicalTrials.gov registry record · Phase 3

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

A Phase 3 study of Adenocarcinoma, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
606
Enrollment target
20
Study locations

NCT00140075 is a Phase 3 study of Adenocarcinoma that has completed, run by Pfizer. The registered enrollment target is 606 participants, above the 73-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (730% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00140075, a Phase 3 study of Adenocarcinoma, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
606 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.

Conditions Studied

Adenocarcinoma

Interventions

  • DRUG Epirubicin with Cyclophosphamide, followed by a Taxane
  • DRUG Epirubicin with a Taxane

Study Locations (20)

Florida

  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Kissimmee
  • Pfizer Investigational Site - Lake Worth
  • Pfizer Investigational Site - Lecanto
  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Miami Shores
  • Pfizer Investigational Site - Port Saint Lucie
  • Pfizer Investigational Site - Tampa

California

  • Pfizer Investigational Site - Bakersfield
  • Pfizer Investigational Site - Berkeley
  • Pfizer Investigational Site - Fountain Valley
  • Pfizer Investigational Site - Fountian Valley
  • Pfizer Investigational Site - Gilroy
  • Pfizer Investigational Site - Poway
  • Pfizer Investigational Site - Soquel

Alabama

  • Pfizer Investigational Site - Mobile

Arizona

  • Pfizer Investigational Site - Tucson

Colorado

  • Pfizer Investigational Site - Colorado Springs

Georgia

  • Pfizer Investigational Site - Atlanta

Trial Details

FieldValue
Enrollment Target 606 participants
Start Date 2000-11
Est. Completion 2006-08
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00140075

The ClinicalTrials.gov registry entry for NCT00140075 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 73-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (730% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Epirubicin with Cyclophosphamide, followed by a Taxane is the first listed.

NCT00140075 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT00140075 about?

NCT00140075 is a clinical study titled "Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer". The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death af...

What is the current status of trial NCT00140075?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2000-11. Estimated completion is 2006-08.

What conditions does trial NCT00140075 study?

This clinical trial studies the following conditions: Adenocarcinoma.

What interventions are being tested in trial NCT00140075?

The interventions under investigation include: Epirubicin with Cyclophosphamide, followed by a Taxane (DRUG), Epirubicin with a Taxane (DRUG).

Who is sponsoring clinical trial NCT00140075?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00140075 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Adenocarcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.